CVS · 8-K · 20261104PR000107

Guidance and Outlook

CVS HEALTH Corp · 2026-11-04 · Importance 83 · Surprise 92 · From source text

CVS Health raised its full-year 2026 GAAP diluted EPS guidance to at least $6.98, from a range of $6.84 to $7.04, and Adjusted EPS guidance to at least $8.20, from $7.90 to $8.10. It raised cash flow from operations guidance to at least $15.5 billion from at least $11.5 billion, and projected full-year revenue of at least $420.0 billion. Management attributed the guidance increases to improvements in the Health Care Benefits and Pharmacy & Consumer Wellness segments, while citing continued elevated cost trends and potential macro headwinds as reasons for caution through the remainder of 2026.

Key facts

• CVS Health raised its 2026 cash flow from operations guidance to at least $15.5 billion from at least $11.5 billion. source
• CVS Health projected 2026 total revenues of at least $420.0 billion. source
• CVS Health raised its 2026 GAAP diluted EPS guidance to at least $6.98 from a range of $6.84 to $7.04. source
• CVS Health raised its 2026 Adjusted EPS guidance to at least $8.20 from a range of $7.90 to $8.10. source
• CVS Health increased full-year 2026 EPS and operating cash flow guidance to reflect increases in Health Care Benefits and Pharmacy & Consumer Wellness, while maintaining a cautious view because of elevated cost trends and potential macro headwinds. source

Impact estimates